The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care
F Saglio, PJ Hanley, CM Bollard - Cytotherapy, 2014 - Elsevier
Adoptive immunotherapy—in particular, T-cell therapy—has recently emerged as a useful
strategy with the potential to overcome many of the limitations of antiviral drugs for the
treatment of viral complications after hematopietic stem cell transplantation. In this review,
we briefly summarize the current methods for virus-specific T-cell isolation or selection and
we report results from clinical trials that have used these techniques, focusing specifically on
the strategies aimed to broaden the application of this technology.
strategy with the potential to overcome many of the limitations of antiviral drugs for the
treatment of viral complications after hematopietic stem cell transplantation. In this review,
we briefly summarize the current methods for virus-specific T-cell isolation or selection and
we report results from clinical trials that have used these techniques, focusing specifically on
the strategies aimed to broaden the application of this technology.